$4.39
2.09% day before yesterday
Nasdaq, Aug 22, 10:18 pm CET

AbCellera Biologics Inc Stock price

$4.39
-0.53 10.77% 1M
+1.40 46.82% 6M
+1.46 49.83% YTD
+1.88 74.90% 1Y
-6.62 60.13% 3Y
-15.61 78.05% 5Y
-15.61 78.05% 10Y
-15.61 78.05% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.09 2.09%

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$758.8m
Net debt
positive
Cash
$553.1m
Shares outstanding
298.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
39.9 | 60.8
EV/Sales
23.1 | 35.2
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
77.6%
Return on Equity
-15.4%
ROCE
-20.9%
ROIC
-29.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$32.9m | $21.6m
EBITDA
$-218.4m | $-239.4m
EBIT
$-278.7m | $-261.8m
Net Income
$-165.7m | $-204.1m
Free Cash Flow
$-139.0m
Growth (TTM | estimate)
Revenue
-0.5% | -25.2%
EBITDA
-1.7% | -6.9%
EBIT
-3.5% | 16.8%
Net Income
-8.1% | -25.3%
Free Cash Flow
18.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-664.3% | -1,109.7%
EBIT
-847.6%
Net
-503.9% | -946.2%
Free Cash Flow
-422.8%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
17.3%
Employees
596
Rev per Employee
$50.0k
Show more

Is AbCellera Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

AbCellera Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a AbCellera Biologics Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a AbCellera Biologics Inc forecast:

Buy
86%
Hold
14%

Financial data from AbCellera Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
33 33
1% 1%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 83 83
2% 2%
251%
- Research and Development Expense 169 169
1% 1%
513%
-218 -218
2% 2%
-664%
- Depreciation and Amortization 60 60
10% 10%
183%
EBIT (Operating Income) EBIT -279 -279
3% 3%
-848%
Net Profit -166 -166
8% 8%
-504%

In millions USD.

Don't miss a Thing! We will send you all news about AbCellera Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbCellera Biologics Inc Stock News

Neutral
Business Wire
12 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in September.
Neutral
Seeking Alpha
17 days ago
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Andrew Booth - Chief Financial Officer Carl L.G. Hansen - CEO, President & Chairperson Tryn T.
Neutral
Business Wire
17 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2025 Business Results & Initiation of a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms.
More AbCellera Biologics Inc News

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Carl Hansen
Employees 596
Founded 2012
Website www.abcellera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today